Literature DB >> 20623445

Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions.

Y J Kim1, J C Park, J-H Kim, S K Shin, S K Lee, Y C Lee, J B Chung.   

Abstract

BACKGROUND AND STUDY AIMS: Controversy persists around the treatment of gastric low-grade dysplasia (LGD). The aim of this study was to investigate possible indications for the endoscopic resection of gastric LGD through analysis of the histologic discrepancies between specimens of gastric LGD obtained by forceps biopsy and by endoscopic mucosal resection (EMR), and of their clinicopathologic characteristics. PATIENTS AND METHODS: The study involved 293 gastric LGD that were histologically proven on the basis of forceps biopsy in Severance Hospital between January 2004 and December 2007. Twenty cases were regularly followed up, and the remaining 273 were resected by EMR. We performed univariate and multivariate analyses of clinical and endoscopic characteristics including lesion size, number of biopsy fragments, and endoscopic appearance, in order to analyze the factors affecting histologic discrepancies.
RESULTS: Of the 273 lesions resected by EMR, 207 (75.8 %) showed concordant histology, whereas for 51 (18.7 %) the histology was upgraded after endoscopic resection. Lesion size, absence of whitish discoloration, and the presence of spontaneous bleeding were found by univariate analysis to be statistically significant factors predicting an upgraded histology after EMR ( P = 0.026, P < 0.001, and P = 0.025, respectively). Multivariate analysis also showed absence of whitish discoloration to be a statistically significant factor influencing histologic discrepancies ( P = 0.001, odds ratio 5.29, 95 % confidence interval 1.95 - 14.37). Perforation and bleeding rates associated with EMR for LGD were 0.7 % and 6.2 %, respectively. Twenty patients who did not undergo EMR were followed up for a mean of 22 months, and 3 were revealed to have adenocarcinoma and 1 high-grade dysplasia on the latest histologic exam.
CONCLUSIONS: We should consider endoscopic resection for gastric LGD that are 2 cm or more in size and do not have whitish discoloration. Georg Thieme Verlag KG Stuttgart . New York.

Entities:  

Mesh:

Year:  2010        PMID: 20623445     DOI: 10.1055/s-0030-1255524

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  37 in total

1.  Gastric adenoma with low-grade dysplasia: two countries, two outcomes.

Authors:  Sun-Young Lee
Journal:  Dig Dis Sci       Date:  2013-09-20       Impact factor: 3.199

Review 2.  Optimal management of biopsy-proven low-grade gastric dysplasia.

Authors:  Jung-Wook Kim; Jae Young Jang
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

3.  Discrepancies in histologic diagnoses of early gastric cancer between biopsy and endoscopic mucosal resection specimens.

Authors:  Madoka Takao; Naomi Kakushima; Kohei Takizawa; Masaki Tanaka; Yuichiro Yamaguchi; Hiroyuki Matsubayashi; Kimihide Kusafuka; Hiroyuki Ono
Journal:  Gastric Cancer       Date:  2011-08-04       Impact factor: 7.370

4.  Clinicopathologic factors and outcomes of histologic discrepancy between differentiated and undifferentiated types after endoscopic resection of early gastric cancer.

Authors:  Choong Nam Shim; Hyunki Kim; Dong Wook Kim; Hyun Soo Chung; Jun Chul Park; Hyuk Lee; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee
Journal:  Surg Endosc       Date:  2014-02-01       Impact factor: 4.584

5.  Long-Term Outcome After Endoscopic Submucosal Dissection for Early Gastric Cancer in Non-neoplastic Pathology Results.

Authors:  Yong Hwan Kwon; Seong Woo Jeon; Su Youn Nam; Hyun Seok Lee; Jeong Shik Kim; Ji Young Park
Journal:  Dig Dis Sci       Date:  2017-03-10       Impact factor: 3.199

6.  Endoscopic resection as a first therapy for gastric epithelial atypia: is it reasonable?

Authors:  Chung Hoon Yu; Seong Woo Jeon; Sung Kook Kim; Hyun Seok Lee; Jun Heo; Yong Hwan Kwon; Gyu Young Kim; Sun Zoo Kim; Han Ik Bae
Journal:  Dig Dis Sci       Date:  2014-06-14       Impact factor: 3.199

7.  Endoscopic features suggesting gastric cancer in biopsy-proven gastric adenoma with high-grade neoplasia.

Authors:  Jung Ho Kim; Yoon Jae Kim; Jungsuk An; Jong Joon Lee; Jae Hee Cho; Kyoung Oh Kim; Jun-Won Chung; Kwang An Kwon; Dong Kyun Park; Ju Hyun Kim
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

8.  Comparative study of Western and Japanese criteria for biopsy-based diagnosis of gastric epithelial neoplasia.

Authors:  Masao Yoshida; Tadakazu Shimoda; Kimihide Kusafuka; Takashi Sugino; Takashi Nakajima; Hiroyuki Ono
Journal:  Gastric Cancer       Date:  2014-05-01       Impact factor: 7.370

9.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

10.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.